the implications of recent datasets for the current and future management of nsclc egfr mutations
Published 1 month ago • 141 plays • Length 58:19Download video MP4
Download video MP3
Similar videos
-
58:14
the implications of recent datasets for the current and future management of non-small cell lung ...
-
1:00:08
the implications of recent datasets for the current and future use of nontargeted therapy for met...
-
58:20
the implications of recent datasets for the current and future management of non-small cell lung ...
-
42:46
the implications of recent datasets for the current and future management of small cell lung canc...
-
42:46
the implications of recent datasets for the current and future management of small cell lung cancer
-
58:14
recent datasets for the current and future mgmt of nsclc with actionable targets beyond egfr
-
1:02:25
implications of recent datasets for the current and future management of gastrointestinal cancers
-
2:03:23
current and future management of non-small cell lung cancer with an egfr mutation
-
2:40
lung cancer adenocarcinoma stage 4 update sept 2014
-
2:15:06
second annual “living with egfr-mutant lung cancer: a virtual forum for patients and caregivers”
-
14:24
egfr-mutant lung cancer & treatment options | 2023 living with egfr-mutant lung cancer patient forum
-
1:00:08
recent datasets for the current and future use of nontargeted therapy for metastatic nsclc
-
1:21
detectability of uncommon egfr mutations in nsclc: ngs versus pcr
-
1:39:03
everything you need to know about biomarker testing and treatment of genomically altered nsclc
-
2:03:01
current and future management of non-small cell lung cancer with an egfr mutation
-
1:25
current treatment recommendations and future directions for egfr-mutant nsclc
-
6:56
first-line therapy in the patient with egfr-mutant lung cancer
-
12:58
egfr inhibitor therapy in second line
-
5:01
chemotherapy-tki combinations in metastatic egfr lung cancer
-
6:41
egfr-positive nsclc: treatment at progression
-
1:02:40
new milestones and changing standards of care in early egfr-mutated nsclc
-
2:45
activity of egfr tkis in patients with nsclc with uncommon egfr mutations